The moderate hypofractionated radiotherapy course (3-weeks with concomitant boost) resulted in comparable safety and efficacy to the normal fractionation (4-6 weeks) course of radiation in the post operative therapy for early breast cancer with high risk of recurrence.

The results of the phase III randomized NRG Oncology/RTOG 1005 trial, were presented by Vicini et al at the 2022 ASTRO meeting after a median follow-up of 7.3 years, the hypofractionated course was found to be non-inferior to the longer treatment for the primary endpoint, in-breast tumor recurrence with 5 year 1.9% vs 2% (P for non-inferiority = .039) with similar grade > 3 side effects rates (3.5% vs 3.3% respectively). In addition, there was no significant difference in terms of cosmetic outcomes.